Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
202.20
+3.68 (1.85%)
Sep 1, 2026, 10:14 AM EDT - Market open
Axsome Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 319.85 | 322.93 | 315.35 | 386.19 | 200.84 | 86.47 |
Cash & Short-Term Investments | 319.85 | 322.93 | 315.35 | 386.19 | 200.84 | 86.47 |
Cash Growth | 5.56% | 2.40% | -18.34% | 92.29% | 132.26% | -52.97% |
Receivables | 277.46 | 224.46 | 142 | 94.82 | 37.7 | - |
Inventory | 37.88 | 27.94 | 15.73 | 15.14 | 4.32 | - |
Prepaid Expenses | 21.38 | 13.65 | 11.98 | 8.12 | 2.78 | 0.05 |
Total Current Assets | 656.57 | 588.99 | 485.06 | 504.26 | 245.64 | 86.52 |
Property, Plant & Equipment | 20.03 | 21.42 | 5.97 | 7.62 | 1.14 | 0.94 |
Goodwill | 12.04 | 12.04 | 12.04 | 12.04 | 10.31 | - |
Other Intangible Assets | 37.36 | 40.52 | 46.89 | 53.29 | 59.66 | - |
Other Long-Term Assets | 35.45 | 26.84 | 18.53 | 11.03 | 14.72 | 0.32 |
Total Assets | 761.45 | 689.81 | 568.5 | 588.24 | 331.48 | 87.79 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 78.97 | 65.54 | 72 | 40.68 | 38.61 | 13.15 |
Accrued Expenses | 294.15 | 230.21 | 145.61 | 90.5 | 51.63 | 9.3 |
Short-Term Debt | 70 | 70 | - | - | - | - |
Current Portion of Leases | 6.13 | 2.98 | 3.26 | 1.27 | 0.43 | 0.62 |
Current Income Taxes Payable | - | 0.1 | 0.96 | - | - | - |
Other Current Liabilities | 11.2 | 10.01 | 8.29 | 6.41 | 5.9 | - |
Total Current Liabilities | 460.45 | 378.84 | 230.1 | 138.85 | 96.56 | 23.07 |
Long-Term Debt | 117.96 | 117.75 | 180.71 | 178.07 | 94.26 | 49.09 |
Long-Term Leases | 30.6 | 27.39 | 8.99 | 7.04 | - | - |
Other Long-Term Liabilities | 69.14 | 77.54 | 91.68 | 73.3 | 31.1 | - |
Total Liabilities | 678.14 | 601.51 | 511.48 | 397.26 | 221.92 | 72.15 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-In Capital | 1,505 | 1,394 | 1,180 | 1,027 | 705.89 | 424.83 |
Retained Earnings | -1,422 | -1,306 | -1,123 | -835.57 | -596.33 | -409.2 |
Shareholders' Equity | 83.3 | 88.3 | 57.02 | 190.98 | 109.56 | 15.63 |
Total Liabilities & Equity | 761.45 | 689.81 | 568.5 | 588.24 | 331.48 | 87.79 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 224.69 | 218.11 | 192.96 | 186.37 | 94.68 | 49.71 |
Net Cash (Debt) | 95.16 | 104.82 | 122.4 | 199.82 | 106.16 | 36.76 |
Net Cash Growth | 11.02% | -14.36% | -38.75% | 88.23% | 188.77% | -72.51% |
Net Cash Per Share | 1.87 | 2.11 | 2.55 | 4.40 | 2.61 | 0.98 |
Filing Date Shares Outstanding | 52.38 | 51.15 | 48.77 | 47.37 | 43.52 | 38.48 |
Total Common Shares Outstanding | 52.3 | 50.88 | 48.67 | 47.35 | 43.5 | 37.82 |
Working Capital | 196.12 | 210.15 | 254.96 | 365.41 | 149.08 | 63.45 |
Book Value Per Share | 1.59 | 1.74 | 1.17 | 4.03 | 2.52 | 0.41 |
Tangible Book Value | 33.9 | 35.73 | -1.92 | 125.65 | 39.59 | 15.63 |
Tangible Book Value Per Share | 0.65 | 0.70 | -0.04 | 2.65 | 0.91 | 0.41 |